Orfoglipron is a novel oral small-molecule that is attracting significant interest from the scientific community because of its potential in research on appetite regulation, weight control and glucose-insulin metabolism.
Original price was: 119.00 €.99.00 €Current price is: 99.00 €.
1-3 business days
Orforglipron is investment-grade, oral GLP-1 receptor agonist, which was developed to treat obesity and type 2 diabetes. It is a small-molecule substance that does not require injections, so it can be taken once a day in tablet form. This form is a significant improvement over classical GLP-1 agonists, which are usually peptides and require subcutaneous administration. Orforglipron binds to the GLP-1 receptor, resulting in increased glucose-dependent insulin secretion, decreased glucagon secretion, slower gastric emptying, increased satiety and weight reduction. For this reason, it has the potential to improve glycemic control and help reduce weight in people with obesity or metabolic disorders.
See also Retatrutide 4mg reagent
As of today, GLP1 Orforglipron is not officially approved for sale as a drug in the EU, the US or Europe. The substance is still in the clinical trial phase and is only available in the research programs and clinical trials. On the Internet you can find offers to sell Orforglipron labeled as „for scientific research” or „for research use only”.”, but such products do not have the status of an authorized drug, are not intended for use in humans and their use is not recommended. The purchase of such reagents is intended only for laboratories and research units for scientific and analytical purposes, and these products are not intended for use in humans or for therapeutic purposes.
Because Orforglipron GLP-1 is not yet an approved drug, there are no official pharmacy or reimbursement price lists. However, on the Internet - outside the market for approved drugs - preparations known as Orforglipron can be found in the form of research reagents (research chemicals). Such preparations are sold by various laboratory trade networks, and their prices vary, for example. approx. $299 for a package labeled Orforglipron tablets offered by some online stores (which is not an endorsement of quality, safety or legal sale as a drug). This price does not reflect the cost of treatment, but only the cost of purchasing a research reagent, which is not a drug approved for human therapy.
Oral GLP-1 Orfoglipron does not have an approved therapeutic dosage, as it is still not a registered drug, and the all dosage information used is from phase 2 and 3 clinical trials only. During these studies, orfoglipron was administered orally once a day and could be taken independently of meals, with no specific recommendations for sipping. The study evaluated doses of 3 mg, 6 mg, 12 mg and 36 mg per day, observing a clear dose-effect relationship. Higher doses were associated with greater weight reduction and better glycemic control, but at the same time were more likely to cause gastrointestinal side effects. Gradual dose escalation was used in some studies to improve treatment tolerability.
Available data from clinical trials suggest that the GLP-1 safety profile of Orforglipron is similar to other GLP-1 agonists in terms of common side effects. The most commonly observed side effects were gastrointestinal complaints, such as nausea, diarrhea, constipation, flatulence or vomiting. In most cases, these activities were mild or moderate and often decreased with continued treatment. The full safety profile of the drug is still being evaluated in phase 3 studies, which also include analysis of metabolic parameters and potential cardiometabolic events
Information sources:
New England Journal of Medicine (2023)
Phase 2 study evaluating the efficacy and safety of oral orfogliprone in obese subjects.
https://www.nejm.org/doi/full/10.1056/NEJMoa2302392
The Lancet / PubMed (2023)
A multicenter, randomized phase 2 study in patients with type 2 diabetes analyzing dose-effect relationship and treatment tolerability.
https://pubmed.ncbi.nlm.nih.gov/37369232/
New England Journal of Medicine (2025)
Phase 3 study evaluating weight reduction, cardiometabolic parameters, and safety of orfogliprone.
https://www.nejm.org/doi/full/10.1056/NEJMoa2511774
INTENDED FOR RESEARCH PURPOSES!
All properties mentioned above are observed with laboratory tests, not done on humans, and are for informational purposes only. Any information contained in the descriptions has not been approved by GIS, GIF or EFSA. The substance is not a drug, food product or dietary supplement, consequently it is not suitable for human consumption. The product qualifies as a chemical reagent / reference material approved for marketing in the EU. It can only be used for scientific research. For other information on the agent, please refer to the Material Safety Data Sheet, which is available for review. The products are available only to institutions or individuals who are associated with research or laboratory activities.
Orforglipron (Oral GLP-1) 5 mg 60 caps
| 5 gwiazdek | 87% | |
| 4 gwiazdki | 9% | |
| 3 gwiazdki | 3% | |
| 2 gwiazdki | 1% | |
| 1 gwiazdka | 0% |
Beest peptides shop. Thanks from Spain :)
good stuff!
Posso acquistare senza ricetta?
11/10 😉
weniger cravings und mehr energie alles gut
tbh i feel less hungry and more energetic now
Support mega freundlich, schnell antw, echt top
didnt expect much but honestly works pretty good
bestellung kam fix alles ok kein probs
Sehr schnelle Lieferung und alles problemlos.
About
DHL Shipping
FedEx Shipping
Check out our other suggestions. Choose the product best suited to your goals.
